Compile Data Set for Download or QSAR
Report error Found 202 Enz. Inhib. hit(s) with all data for entry = 636
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM284757(US10023575, Example 48 | US10023575, Example 49 | ...)
Affinity DataIC50: 1.20nMT: 2°CAssay Description:All reactions were performed in 384 well plates, Perkin Elmer black optiplates and IMAP reaction buffer with 0.1% Tween20 (kit component)Compounds we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/10/2019
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM284757(US10023575, Example 48 | US10023575, Example 49 | ...)
Affinity DataIC50: 1.35nMT: 2°CAssay Description:All reactions were performed in 384 well plates, Perkin Elmer black optiplates and IMAP reaction buffer with 0.1% Tween20 (kit component)Compounds we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/10/2019
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM284755(US10023575, Example 46 | US10023575, Example 47 | ...)
Affinity DataIC50: 3.40nMT: 2°CAssay Description:All reactions were performed in 384 well plates, Perkin Elmer black optiplates and IMAP reaction buffer with 0.1% Tween20 (kit component)Compounds we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/10/2019
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM284762(US10023575, Example 86a | US10023575, Example 85a ...)
Affinity DataIC50: 3.90nMT: 2°CAssay Description:All reactions were performed in 384 well plates, Perkin Elmer black optiplates and IMAP reaction buffer with 0.1% Tween20 (kit component)Compounds we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/10/2019
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM284755(US10023575, Example 46 | US10023575, Example 47 | ...)
Affinity DataIC50: 5.70nMT: 2°CAssay Description:All reactions were performed in 384 well plates, Perkin Elmer black optiplates and IMAP reaction buffer with 0.1% Tween20 (kit component)Compounds we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/10/2019
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM284764(US10023575, Example 55 | US10023575, Example 84a |...)
Affinity DataIC50: 5.90nMT: 2°CAssay Description:All reactions were performed in 384 well plates, Perkin Elmer black optiplates and IMAP reaction buffer with 0.1% Tween20 (kit component)Compounds we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/10/2019
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM284767(US10023575, Example 58 | US10023575, Example 93a |...)
Affinity DataIC50: 11nMT: 2°CAssay Description:All reactions were performed in 384 well plates, Perkin Elmer black optiplates and IMAP reaction buffer with 0.1% Tween20 (kit component)Compounds we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/10/2019
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM284739(US10023575, Example 30 | US10479794, Example 30 | ...)
Affinity DataIC50: 12nMT: 2°CAssay Description:All reactions were performed in 384 well plates, Perkin Elmer black optiplates and IMAP reaction buffer with 0.1% Tween20 (kit component)Compounds we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/10/2019
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM284762(US10023575, Example 86a | US10023575, Example 85a ...)
Affinity DataIC50: 12nMT: 2°CAssay Description:All reactions were performed in 384 well plates, Perkin Elmer black optiplates and IMAP reaction buffer with 0.1% Tween20 (kit component)Compounds we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/10/2019
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM284777(US10023575, Example 68 | US10023575, Example 69 | ...)
Affinity DataIC50: 13nMT: 2°CAssay Description:All reactions were performed in 384 well plates, Perkin Elmer black optiplates and IMAP reaction buffer with 0.1% Tween20 (kit component)Compounds we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/10/2019
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM284710(US10023575, Example 1 | US10479794, Example 1 | US...)
Affinity DataIC50: 14nMT: 2°CAssay Description:All reactions were performed in 384 well plates, Perkin Elmer black optiplates and IMAP reaction buffer with 0.1% Tween20 (kit component)Compounds we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/10/2019
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM284767(US10023575, Example 58 | US10023575, Example 93a |...)
Affinity DataIC50: 14nMT: 2°CAssay Description:All reactions were performed in 384 well plates, Perkin Elmer black optiplates and IMAP reaction buffer with 0.1% Tween20 (kit component)Compounds we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/10/2019
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM284770(US10023575, Example 61 | US10023575, Example 90a |...)
Affinity DataIC50: 14nMT: 2°CAssay Description:All reactions were performed in 384 well plates, Perkin Elmer black optiplates and IMAP reaction buffer with 0.1% Tween20 (kit component)Compounds we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/10/2019
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM284770(US10023575, Example 61 | US10023575, Example 90a |...)
Affinity DataIC50: 19nMT: 2°CAssay Description:All reactions were performed in 384 well plates, Perkin Elmer black optiplates and IMAP reaction buffer with 0.1% Tween20 (kit component)Compounds we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/10/2019
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM284764(US10023575, Example 55 | US10023575, Example 84a |...)
Affinity DataIC50: 21nMT: 2°CAssay Description:All reactions were performed in 384 well plates, Perkin Elmer black optiplates and IMAP reaction buffer with 0.1% Tween20 (kit component)Compounds we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/10/2019
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM284711(US10023575, Example 2 | US10479794, Example 2 | US...)
Affinity DataIC50: 22nMT: 2°CAssay Description:All reactions were performed in 384 well plates, Perkin Elmer black optiplates and IMAP reaction buffer with 0.1% Tween20 (kit component)Compounds we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/10/2019
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM284769(US10023575, Example 60 | US10479794, Example 60 | ...)
Affinity DataIC50: 22nMT: 2°CAssay Description:All reactions were performed in 384 well plates, Perkin Elmer black optiplates and IMAP reaction buffer with 0.1% Tween20 (kit component)Compounds we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/10/2019
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM284777(US10023575, Example 68 | US10023575, Example 69 | ...)
Affinity DataIC50: 24nMT: 2°CAssay Description:All reactions were performed in 384 well plates, Perkin Elmer black optiplates and IMAP reaction buffer with 0.1% Tween20 (kit component)Compounds we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/10/2019
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM284775(US10023575, Example 66 | US10479794, Example 66 | ...)
Affinity DataIC50: 25nMT: 2°CAssay Description:All reactions were performed in 384 well plates, Perkin Elmer black optiplates and IMAP reaction buffer with 0.1% Tween20 (kit component)Compounds we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/10/2019
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM284743(US10023575, Example 34 | US10479794, Example 34 | ...)
Affinity DataIC50: 27nMT: 2°CAssay Description:All reactions were performed in 384 well plates, Perkin Elmer black optiplates and IMAP reaction buffer with 0.1% Tween20 (kit component)Compounds we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/10/2019
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM284740(US10023575, Example 31 | US10479794, Example 31 | ...)
Affinity DataIC50: 30nMT: 2°CAssay Description:All reactions were performed in 384 well plates, Perkin Elmer black optiplates and IMAP reaction buffer with 0.1% Tween20 (kit component)Compounds we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/10/2019
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM284774(US10023575, Example 65 | US10479794, Example 65 | ...)
Affinity DataIC50: 30nMT: 2°CAssay Description:All reactions were performed in 384 well plates, Perkin Elmer black optiplates and IMAP reaction buffer with 0.1% Tween20 (kit component)Compounds we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/10/2019
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM284744(US10023575, Example 35 | US10479794, Example 35 | ...)
Affinity DataIC50: 31nMT: 2°CAssay Description:All reactions were performed in 384 well plates, Perkin Elmer black optiplates and IMAP reaction buffer with 0.1% Tween20 (kit component)Compounds we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/10/2019
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM284760(US10023575, Example 51 | BDBM284800 | US10479794, ...)
Affinity DataIC50: 32nMT: 2°CAssay Description:All reactions were performed in 384 well plates, Perkin Elmer black optiplates and IMAP reaction buffer with 0.1% Tween20 (kit component)Compounds we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/10/2019
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM284726(US10023575, Example 17 | US10479794, Example 17 | ...)
Affinity DataIC50: 39nMT: 2°CAssay Description:All reactions were performed in 384 well plates, Perkin Elmer black optiplates and IMAP reaction buffer with 0.1% Tween20 (kit component)Compounds we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/10/2019
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM284757(US10023575, Example 48 | US10023575, Example 49 | ...)
Affinity DataIC50: 40nMT: 2°CAssay Description:All reactions were performed in 384 well plates, Perkin Elmer black optiplates and IMAP reaction buffer with 0.1% Tween20 (kit component)Compounds we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/10/2019
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM284781(US10023575, Example 72 | US10023575, Example 73 | ...)
Affinity DataIC50: 42nMT: 2°CAssay Description:All reactions were performed in 384 well plates, Perkin Elmer black optiplates and IMAP reaction buffer with 0.1% Tween20 (kit component)Compounds we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/10/2019
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM284713(US10023575, Example 4 | US10479794, Example 4 | US...)
Affinity DataIC50: 48nMT: 2°CAssay Description:All reactions were performed in 384 well plates, Perkin Elmer black optiplates and IMAP reaction buffer with 0.1% Tween20 (kit component)Compounds we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/10/2019
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM284776(US10023575, Example 67 | US10479794, Example 67 | ...)
Affinity DataIC50: 50nMT: 2°CAssay Description:All reactions were performed in 384 well plates, Perkin Elmer black optiplates and IMAP reaction buffer with 0.1% Tween20 (kit component)Compounds we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/10/2019
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM284760(US10023575, Example 51 | BDBM284800 | US10479794, ...)
Affinity DataIC50: 59nMT: 2°CAssay Description:All reactions were performed in 384 well plates, Perkin Elmer black optiplates and IMAP reaction buffer with 0.1% Tween20 (kit component)Compounds we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/10/2019
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM284768(US10023575, Example 59 | US10479794, Example 59 | ...)
Affinity DataIC50: 60nMT: 2°CAssay Description:All reactions were performed in 384 well plates, Perkin Elmer black optiplates and IMAP reaction buffer with 0.1% Tween20 (kit component)Compounds we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/10/2019
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM284771(US10023575, Example 62 | US10023575, Example 91a |...)
Affinity DataIC50: 63nMT: 2°CAssay Description:All reactions were performed in 384 well plates, Perkin Elmer black optiplates and IMAP reaction buffer with 0.1% Tween20 (kit component)Compounds we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/10/2019
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM284741(US10023575, Example 32 | US10479794, Example 32 | ...)
Affinity DataIC50: 67nMT: 2°CAssay Description:All reactions were performed in 384 well plates, Perkin Elmer black optiplates and IMAP reaction buffer with 0.1% Tween20 (kit component)Compounds we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/10/2019
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM284717(US10023575, Example 8 | US10479794, Example 8 | US...)
Affinity DataIC50: 69nMT: 2°CAssay Description:All reactions were performed in 384 well plates, Perkin Elmer black optiplates and IMAP reaction buffer with 0.1% Tween20 (kit component)Compounds we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/10/2019
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM284757(US10023575, Example 48 | US10023575, Example 49 | ...)
Affinity DataIC50: 70nMT: 2°CAssay Description:All reactions were performed in 384 well plates, Perkin Elmer black optiplates and IMAP reaction buffer with 0.1% Tween20 (kit component)Compounds we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/10/2019
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM284730(US10023575, Example 21 | US10479794, Example 21 | ...)
Affinity DataIC50: 74nMT: 2°CAssay Description:All reactions were performed in 384 well plates, Perkin Elmer black optiplates and IMAP reaction buffer with 0.1% Tween20 (kit component)Compounds we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/10/2019
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM284749(US10023575, Example 40 | US10023575, Example 80a |...)
Affinity DataIC50: 75nMT: 2°CAssay Description:All reactions were performed in 384 well plates, Perkin Elmer black optiplates and IMAP reaction buffer with 0.1% Tween20 (kit component)Compounds we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/10/2019
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM284716(US10023575, Example 7 | US10479794, Example 7 | US...)
Affinity DataIC50: 77nMT: 2°CAssay Description:All reactions were performed in 384 well plates, Perkin Elmer black optiplates and IMAP reaction buffer with 0.1% Tween20 (kit component)Compounds we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/10/2019
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM284719(US10023575, Example 10 | US10479794, Example 10 | ...)
Affinity DataIC50: 80nMT: 2°CAssay Description:All reactions were performed in 384 well plates, Perkin Elmer black optiplates and IMAP reaction buffer with 0.1% Tween20 (kit component)Compounds we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/10/2019
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM284742(US10023575, Example 33 | US10479794, Example 33 | ...)
Affinity DataIC50: 83nMT: 2°CAssay Description:All reactions were performed in 384 well plates, Perkin Elmer black optiplates and IMAP reaction buffer with 0.1% Tween20 (kit component)Compounds we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/10/2019
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM284749(US10023575, Example 40 | US10023575, Example 80a |...)
Affinity DataIC50: 84nMT: 2°CAssay Description:All reactions were performed in 384 well plates, Perkin Elmer black optiplates and IMAP reaction buffer with 0.1% Tween20 (kit component)Compounds we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/10/2019
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM284734(US10023575, Example 25 | US10479794, Example 25 | ...)
Affinity DataIC50: 88nMT: 2°CAssay Description:All reactions were performed in 384 well plates, Perkin Elmer black optiplates and IMAP reaction buffer with 0.1% Tween20 (kit component)Compounds we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/10/2019
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM284767(US10023575, Example 58 | US10023575, Example 93a |...)
Affinity DataIC50: 93nMT: 2°CAssay Description:All reactions were performed in 384 well plates, Perkin Elmer black optiplates and IMAP reaction buffer with 0.1% Tween20 (kit component)Compounds we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/10/2019
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM284762(US10023575, Example 86a | US10023575, Example 85a ...)
Affinity DataIC50: 100nMT: 2°CAssay Description:All reactions were performed in 384 well plates, Perkin Elmer black optiplates and IMAP reaction buffer with 0.1% Tween20 (kit component)Compounds we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/10/2019
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM284766(US10023575, Example 57 | US10479794, Example 57 | ...)
Affinity DataIC50: 103nMT: 2°CAssay Description:All reactions were performed in 384 well plates, Perkin Elmer black optiplates and IMAP reaction buffer with 0.1% Tween20 (kit component)Compounds we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/10/2019
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM284718(US10023575, Example 9 | US10479794, Example 9 | US...)
Affinity DataIC50: 117nMT: 2°CAssay Description:All reactions were performed in 384 well plates, Perkin Elmer black optiplates and IMAP reaction buffer with 0.1% Tween20 (kit component)Compounds we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/10/2019
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM284731(US10023575, Example 22 | US10479794, Example 22 | ...)
Affinity DataIC50: 119nMT: 2°CAssay Description:All reactions were performed in 384 well plates, Perkin Elmer black optiplates and IMAP reaction buffer with 0.1% Tween20 (kit component)Compounds we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/10/2019
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM284764(US10023575, Example 55 | US10023575, Example 84a |...)
Affinity DataIC50: 120nMT: 2°CAssay Description:All reactions were performed in 384 well plates, Perkin Elmer black optiplates and IMAP reaction buffer with 0.1% Tween20 (kit component)Compounds we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/10/2019
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM284781(US10023575, Example 72 | US10023575, Example 73 | ...)
Affinity DataIC50: 122nMT: 2°CAssay Description:All reactions were performed in 384 well plates, Perkin Elmer black optiplates and IMAP reaction buffer with 0.1% Tween20 (kit component)Compounds we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/10/2019
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM284772(US10023575, Example 63 | US10479794, Example 63 | ...)
Affinity DataIC50: 124nMT: 2°CAssay Description:All reactions were performed in 384 well plates, Perkin Elmer black optiplates and IMAP reaction buffer with 0.1% Tween20 (kit component)Compounds we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/10/2019
Entry Details
Go to US Patent

Displayed 1 to 50 (of 202 total ) | Next | Last >>
Jump to: